Trials for incontinence treatment begin

18th April 2011

Research into a possible treatment for urinary incontinence began at Beech Tree Labs Inc this week.

Dr John McMichael, chief executive officer of the American laboratory, announced that clinical evaluation of new therapeutic agent UISH001 had started, in a bid to test its effectiveness against incontinence, which statistics show is on the rise.

He said: "The incidence of urinary incontinence is increasing as a consequence, in part, of our aging society. It represents an unmet medical need since most of the products now available are accompanied by adverse effects for a significant number of patients. This phase 2a trial is being conducted to determine if UISH001 can meet that need."

Sixty patients will take part in the FDA-approved placebo-controlled trial, which will follow on from tests showing that the product was effective in treating urge, stress and mixed incontinence.

The NHS describes urinary incontinence as the unintentional passing of urine. It is thought to affect around 50 million people in the developed world. Incontinence affects around 13 per cent of women and five per cent of men in the UK.

Posted by Philip Briggs

Health News is provided by Adfero in collaboration with Spire Healthcare. Please note that all copy above is ©Adfero Ltd. and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.


Find a treatment, test or scan available at:


Find a consultant

Use one or more of the options below to search for a consultant and link through to view their Spire profile.


Let us help you

fill out this form and we will get back to you:

Please select a hospital

We can call you

Please enter your details below and we will call you back.

What is the aim of your enquiry?

Please select a hospital

If we are unable to reach you by phone, please include your email address so that we can get in touch...



© Spire Healthcare Group plc (2016)